Generic Name and Formulations:
Sulindac 150mg, 200mg; scored tabs.
Various generic manufacturers
Indications for Sulindac:
Rheumatoid arthritis. Osteoarthritis. Ankylosing spondylitis. Acute painful shoulder. Acute gouty arthritis.
Take with food. 150mg twice daily. Acute painful shoulder or gouty arthritis: 200mg twice daily, usually for 7–14 days. All: max 400mg/day.
Aspirin allergy. Coronary artery bypass graft surgery.
Advanced renal disease: not recommended. Active or history of GI bleeding, peptic ulcer, or kidney stones. Heart failure. Impaired renal or hepatic function. Edema. Hypertension. Bleeding disorders. Sepsis. Diabetes. Preexisting asthma. Maintain adequate hydration. Monitor blood, hepatic, renal, and ocular function in chronic use. Discontinue if unexplained fever, pancreatitis, or liver dysfunction occurs. Systemic lupus erythematosus and mixed connective tissue disease. Elderly. Debilitated. Pregnancy (Cat.C); avoid in late pregnancy. Nursing mothers: not recommended.
NSAID (indene deriv.).
Increased risk of GI toxicity with aspirin, other NSAIDs, alcohol, smoking. Probenecid increases serum levels. Diflunisal reduces serum levels. Antagonized by, and peripheral neuropathy with, DMSO. Monitor anticoagulants, antihyperglycemics. Caution with methotrexate, cyclosporine, nephrotoxic drugs (increased toxicity). Increased serum lithium levels (monitor). May antagonize diuretics, ACE inhibitors, angiotensin II antagonists (monitor).
GI ulcer/bleeding/pain, dyspepsia, nausea, diarrhea, constipation, rash (discontinue if occurs), dizziness, headache, tinnitus, edema, nephritis, nephrotic syndrome, pancreatitis, jaundice, hepatitis. See literature re: risk of cardiovascular events.
Formerly known under the brand name Clinoril.
Endocrinology Advisor Articles
- Trends in Cardiovascular Deaths for US Adults With and Without Diabetes
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Comparing Efficacies of Second-Line Treatments in Type 2 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency